NCT07391683

Brief Summary

Patients with heart failure undergoing cardiac surgery face a significantly increased perioperative risk, yet no standardized strategy exists to mitigate this risk effectively. Current preoperative management relies on optimization of medical therapy without a structured prehabilitation approach. Given the strong association between eleveated preoperative N-terminal pro-B-type natriuretic peptide levels and postoperative outcomes, patients at increased risk could be identified using this biomarker. Telemedical disease management programs have demonstrated efficacy in outpatient heart failure care, but their role in preoperative optimization remains underexplored. This study aims to assess whether a structured, multidisciplinary, telemedicine-assisted prehabilitation program can reduce perioperative complications, and improve surgical outcomes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
162

participants targeted

Target at P75+ for not_applicable

Timeline
93mo left

Started Feb 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Feb 2026Jan 2034

First Submitted

Initial submission to the registry

January 7, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 6, 2026

Completed
10 days until next milestone

Study Start

First participant enrolled

February 16, 2026

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2029

Expected
4.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2034

Last Updated

February 18, 2026

Status Verified

December 1, 2025

Enrollment Period

3.2 years

First QC Date

January 7, 2026

Last Update Submit

February 17, 2026

Conditions

Keywords

cardiac surgeryheart failureTelemedically Assisted optimization programprehabCardiac Surgical ProceduresPerioperative CarePreoperative ExerciseRemote Patient MonitoringTelemedicine

Outcome Measures

Primary Outcomes (4)

  • Hierachical Endpoint Perioperative Outcome: 30-day mortality

    All-cause mortality from randomization to 30 days post-surgery

    assessed from randomization through 30 days post-surgery,

  • Hierachical Endpoint Perioperative Outcome: ECMO

    Requirement for extracorporeal membrane oxygenation (ECMO) within 30 days post-surgery

    assessed from surgery until 30 days post-surgery

  • Hierachical Endpoint Perioperative Outcome: hemodialysis or ultrafiltration

    Need for hemodialysis or ultrafiltration within 30 days post-surgery

    assessed from surgery until 30 days post-surgery

  • Hierachical Endpoint Perioperative Outcome: stay on ICU

    Length of stay in the intensive care unit (ICU) within 30 days post-surgery

    assessed from surgery until 30 days post-surgery.

Secondary Outcomes (22)

  • Preoperative adverse events: death

    will be assessed on day prior to surgery

  • Preoperative adverse events: hospitalization

    will be assessed on day prior to surgery

  • Preoperative adverse events: urgent surgery necessary

    will be assessed on day prior to surgery

  • Perioperative outcome: 30-day mortality

    will be assessed on day 30 after surgery

  • Perioperative outcome: ECMO

    will be assessed on day 30 after surgery

  • +17 more secondary outcomes

Other Outcomes (6)

  • Safety endpoint: Hyperkalemia

    from randomization to day prior to surgery

  • Safety endpoint: Acute kidney injury

    from randomization to day prior to surgery

  • Safety endpoint: Syncope

    from randomization to day prior to surgery

  • +3 more other outcomes

Study Arms (2)

Control arm - Standard of care treatment

NO INTERVENTION

Receives standard preoperative care until surgery.

PREPARE-HF

EXPERIMENTAL

Preoperative Heart Failure Optimization and Telemedicine Integration

Other: PREPARE-HF disease management program, which includes:

Interventions

1. Heart failure education and training 2. Optimization of guideline-directed medical therapy (GDMT) 3. Telemedical / telenursing / monitoring and therapy adjustments 4. Supervised telemedicine-assisted exercise program

PREPARE-HF

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indication for elective cardiac surgery in the Heart team
  • NTproBNP ≥ 1500 ng/L
  • ≥ 18 years willing to participate in trial
  • Written informed consent

You may not qualify if:

  • Neuropsychiatric disorders / illnesses (e.g. drug addiction, alcohol abuse) that do not allow adherent participation in the study
  • No sufficient ability to measure and transfer data or existing support in the social environment
  • no sufficient ability to communicate (language skills, eyesight, hearing)
  • Pregnancy
  • Chronic kidney disease requiring dialysis
  • Planed procedure: heart transplantation (HTX), implant of left ventricular mechanical assist devices (L-VAD)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Innsbruck - Department of Cardiology & Department of Cardiac Surgery

Innsbruck, Tyrol, 6020, Austria

RECRUITING

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Can Gollmann-Tepeköylü, Prof.

    Medical University of Innsbruck - Department of cardiac surgery

    PRINCIPAL INVESTIGATOR
  • Gerhard Pölzl, Prof.

    Medical University of Innsbruck - Department of cardiology

    PRINCIPAL INVESTIGATOR
  • Christian Puelacher, MD

    Medical University of Innsbruck - Department of cardiology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Can Gollmann-Tepeköylü, Prof.

CONTACT

Leo Winter-Pölzl, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
Blinding is not feasible because the intervention involves overt telemedical monitoring, patient education, and individualized therapeutic adjustments that are readily apparent to both patients and healthcare providers, necessitating an open-label study design.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2026

First Posted

February 6, 2026

Study Start

February 16, 2026

Primary Completion (Estimated)

April 16, 2029

Study Completion (Estimated)

January 1, 2034

Last Updated

February 18, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share
Time Frame
following publication of primary and secondary results
Access Criteria
Data will be shared upon reasonable request.

Locations